Cargando…

Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients

Mutations in the epidermal growth factor receptor (EGFR) are associated with various solid tumors. This study aimed to compare two methods for the detection of EGFR mutations in circulating tumor DNA (ctDNA) from lung adenocarcinoma (LUAD) patients and to evaluate the clinical significance of EGFR m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hung, Ming-Szu, Lung, Jr-Hau, Lin, Yu-Ching, Fang, Yu-Hung, Huang, Shu-Yi, Jiang, Yuan-Yuan, Hsieh, Meng-Jer, Tsai, Ying-Huang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627967/ https://www.ncbi.nlm.nih.gov/pubmed/31185703 http://dx.doi.org/10.3390/cancers11060803

Ejemplares similares

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

(18)F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs
por: Huang, Yu-Erh, et al.
Publicado: (2022)

Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
por: Li, Shih-Hong, et al.
Publicado: (2022)

MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
por: Lung, Jrhau, et al.
Publicado: (2019)

Impact of hypertrophic pulmonary osteoarthropathy on patients with lung cancer
por: Fang, Yu-Hung, et al.
Publicado: (2017)

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer
por: Hung, Ming-Szu, et al.
Publicado: (2016)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells
por: Hung, Ming-Szu, et al.
Publicado: (2016)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study
por: Fang, Yu-Hung, et al.
Publicado: (2019)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
por: Riediger, Anja Lisa, et al.
Publicado: (2016)

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients
por: Buder, Anna, et al.
Publicado: (2021)

A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening
por: Lung, Jrhau, et al.
Publicado: (2020)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with EGFR Mutations
por: Kuo, Chia-Yu, et al.
Publicado: (2019)

Author Correction: A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening
por: Lung, Jrhau, et al.
Publicado: (2021)

The Relationship between Metabolic Syndrome and Plasma Metals Modified by EGFR and TNF-α Gene Polymorphisms
por: Chen, Tzu-Hua, et al.
Publicado: (2021)

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
por: Liang, Sheng-Kai, et al.
Publicado: (2017)

Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma
por: Liu, Xiang-Liang, et al.
Publicado: (2021)

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma
por: Lin, Chun-Yu, et al.
Publicado: (2017)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

The Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells
por: Chuang, Min-Chun, et al.
Publicado: (2021)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang, Wenting, et al.
Publicado: (2018)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Tp53 haploinsufficiency is involved in hotspot mutations and cytoskeletal remodeling in gefitinib-induced drug-resistant EGFR(L858R)-lung cancer mice
por: Wang, Yi-Shiang, et al.
Publicado: (2023)

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
por: Wu, Yi-Long, et al.
Publicado: (2017)

N‐glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC
por: Han, Chia‐Li, et al.
Publicado: (2021)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
por: Chiu, Tzu-Hsuan, et al.
Publicado: (2021)

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
por: Gow, Chien-Hung, et al.
Publicado: (2019)

Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung
por: HUANG, CHU-YUN, et al.
Publicado: (2014)

Low Concentrations of Dehydroepiandrosterone Sulfate are Associated with Depression and Fatigue in Patients with Non-Small-Cell Lung Cancer After Chemotherapy
por: Fang, Yu-Hung, et al.
Publicado: (2020)

Association of EGFR mutations and HMGB1 genetic polymorphisms in lung adenocarcinoma patients
por: Wu, Yi-Liang, et al.
Publicado: (2019)

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
por: Tsai, Ming-Ju, et al.
Publicado: (2023)

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
por: Wu, Shang-Gin, et al.
Publicado: (2017)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ajj3k7ftjorbhng6u4jql848cc